Compare TK & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TK | KALV |
|---|---|---|
| Founded | 1973 | N/A |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 937.1M | 1.0B |
| IPO Year | 1995 | 2014 |
| Metric | TK | KALV |
|---|---|---|
| Price | $11.55 | $26.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.60 |
| AVG Volume (30 Days) | 598.5K | ★ 2.8M |
| Earning Date | 05-13-2026 | 07-09-2026 |
| Dividend Yield | ★ 15.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | N/A | $185.42 |
| Revenue Next Year | N/A | $59.23 |
| P/E Ratio | $13.43 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $7.12 | $9.83 |
| 52 Week High | $14.38 | $26.98 |
| Indicator | TK | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 36.56 | 75.23 |
| Support Level | $11.01 | $14.22 |
| Resistance Level | $14.12 | N/A |
| Average True Range (ATR) | 0.44 | 0.05 |
| MACD | -0.19 | -0.26 |
| Stochastic Oscillator | 10.10 | 87.04 |
Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.